Salute e Benessere
Endometrial Cancer Market Poised for Expansion Throughout Forecast Period (2025-2034) Amid Increasing Adoption of Immunotherapies | DelveInsight
Discover the endometrial cancer new treatment @
Ageing populations plus increases in obesity and metabolic conditions are raising endometrial cancer incidence in many regions — a larger patient pool increases demand for diagnostics, treatment and follow-up care.
Recent regulatory approvals and label expansions (e.g., pembrolizumab with chemotherapy; checkpoint inhibitors for dMMR/MSI-H disease and other indications) are adding higher-cost, high-value therapeutic options and changing standard-of-care pathways. These approvals accelerate uptake and market spending.
Molecular classification (MMR/MSI status, genomic subtyping from projects like TCGA) and companion diagnostics enable patient stratification, biomarker-driven prescribing, and higher use of targeted/immuno therapies — expanding both diagnostic services and personalized-therapy markets.
The most promising assets in endometrial cancer clinical trial include by Merck, by Karyopharm Therapeutics, by Faeth Therapeutics, by AstraZeneca and Daiichi Sankyo, by Hoffmann-La Roche, by Iovance Biotherapeutics, and others.
The primary treatment for endometrial cancer remains hysterectomy. However, in recent years, several drugs, including , which received its first approval in 2021, have gained regulatory clearance in the U.S. for treating this disease. These therapies may be administered either intravenously or orally. Insights from The Cancer Genome Atlas Project (TCGA) have classified endometrial tumors into specific genomic subtypes, particularly dMMR and MSI-H, which serve as reliable prognostic biomarkers. The emergence of treatments tailored to these tumor profiles has significantly transformed the therapeutic landscape for patients with recurrent or advanced endometrial cancer.
Notable advancements include PD-1 inhibitors such as , while the combination received FDA approval in 2022 for use in patients with advanced endometrial cancer that is not dMMR or MSI-H. Conventional therapies still include agents like carboplatin-taxol, megestrol acetate, and medroxyprogesterone acetate. Nevertheless, there remains a pressing need for more effective therapeutic strategies to enhance clinical outcomes. Major companies such as Merck, Karyopharm Therapeutics, Faeth Therapeutics, and GSK are actively pursuing the development of novel candidates across various stages of clinical research.
To know more about endometrial cancer treatment options, visit @
The endometrial cancer pipeline seems to be quite strong. The most promising assets include by Merck, by Karyopharm Therapeutics, by Faeth Therapeutics, by AstraZeneca and Daiichi Sankyo, by Hoffmann-La Roche, by Iovance Biotherapeutics, and others.
is a recombinant humanized IgG1 monoclonal antibody directed against TROP2, conjugated to a topoisomerase I inhibitor. As a third-generation Antibody-Drug Conjugate (ADC), it specifically targets TROP2-expressing cells. The drug is administered intravenously in powder form and utilizes advanced ADC conjugation technology. It is currently in development for the treatment of endometrial carcinoma and other potential indications, with ongoing evaluation in a Phase III clinical trial.
is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound. It binds to and inhibits the nuclear export protein XPO1, resulting in the retention and accumulation of tumor suppressor proteins within the nucleus. This restores and enhances their tumor-suppressing activity, selectively triggering apoptosis in cancer cells while sparing normal cells. Selinexor is being assessed in a Phase III clinical trial (SIENDO study) as a maintenance therapy compared to placebo in patients with endometrial cancer following first- or second-line chemotherapy. Another Phase III trial (XPORT-EC-042) is investigating its use as maintenance treatment for patients with TP53 wild-type advanced or recurrent endometrial cancer, with data expected by mid-2026.
The anticipated launch of these emerging therapies is poised to transform the endometrial cancer market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the endometrial cancer market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about therapy for endometrial cancer @
Endometrial cancer originates in the endometrium, the inner lining of the uterus, and is the most prevalent malignancy of the female reproductive system. The disease typically begins as a pre-invasive intraepithelial lesion, which advances to an invasive form infiltrating the endometrial stroma and eventually extending into the myometrium. As the cancer progresses, it can spread via lymphatic vessels to regional lymph nodes, leading to potential metastasis through vascular pathways. Tumor extension to the uterine cervix and stroma usually occurs through lymphatic dissemination, especially in poorly differentiated carcinomas, though surface spread from cancers located in the lower uterine segment may also take place.
The endometrial cancer epidemiology section provides insights into the historical and current endometrial cancer patient pool and forecasted trends for the leading markets. In Europe , approximately of patients with endometrial cancer have pMMR/MSS tumours. The incidence of endometrial cancer throughout Asia is heterogeneous, with in Japan .
The endometrial cancer market report proffers epidemiological analysis for the study period 2020–2034 in the leading markets, segmented into:
Download the report to understand which factors are driving endometrial cancer therapeutics market trends @
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key endometrial cancer companies, including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key advanced endometrial cancer companies, including among others.
report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key endometriosis companies, including , among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key endometriosis pain companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/endometrial-cancer-market-poised-for-expansion-throughout-forecast-period-20252034-amid-increasing-adoption-of-immunotherapies--delveinsight-302606621.html